Magdy Elkashab

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss.

Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss.

Journal: Hepatology communications

Published: August 29, 2025

Epidemiology, Treatment Patterns and Survival in Canadian Patients With Chronic Hepatitis B-Related Hepatocellular Carcinoma.

Epidemiology, Treatment Patterns and Survival in Canadian Patients With Chronic Hepatitis B-Related Hepatocellular Carcinoma.

Journal: Journal of viral hepatitis

Published: March 08, 2024

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: October 31, 2015

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

Journal: Gastroenterology

Published: June 11, 2015

Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

Journal: Journal of gastroenterology and hepatology

Published: February 25, 2015

Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.

Journal: Canadian journal of gastroenterology & hepatology

Published: November 12, 2013

The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients.

The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients.

Journal: Hepatology international

Published: June 15, 2012

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3.

Journal: Alimentary pharmacology & therapeutics

Published: November 05, 2011

Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.

Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: October 24, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026